Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.69 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792413 | 1.00 | BRD4 (0.69) | BRD4NOS3NOS1NOS2FYN | |
| SCHEMBL28740036 | 0.85 | BRD4 (0.61) | BRD4 | |
| SCHEMBL2052953 | 0.83 | BRD4 (0.69) | BRD4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21964862 | 0.83 | — | — | |
| SCHEMBL5709310 | 0.83 | — | — | |
| SCHEMBL18821186 | 0.83 | — | — | |
| SCHEMBL23103442 | 0.80 | BRD4 (0.46) | BRD4NOS3NOS1NOS2FYN | |
| SCHEMBL21475939 | 0.80 | BRD4 (0.46) | BRD4NOS3NOS1NOS2 | |
| SCHEMBL21881953 | 0.80 | BRD4 (0.46) | BRD4NOS3NOS1NOS2FYN | |
| SCHEMBL24493463 | 0.80 | BRD4 (0.46) | BRD4NOS3NOS1NOS2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| WO-2020051796-A1 | PREPARATION METHOD FOR BRIVARACETAM AND INTERMEDIATE THEREOF | 上海宣泰医药科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| US-20180125818-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2018-01-18 | — | — | US | disclosed |
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160030391-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2968237-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968220-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Agenebio, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968257-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144546-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144663-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014078568-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-05-22 | — | — | WO | disclosed |
| EP-2672822-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2533645-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012109491-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2011100373-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-2308870-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308867-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| EP-1386912-B1 | CYCLIC AMIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271108-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, BACE1, GRIN2A | BRD4 2553/4885NOS3 4318/4885NOS1 4059/4885 |
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | BRD4 2553/4885NOS3 4318/4885NOS1 4059/4885 |
| US-20180015109-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | BRD4 3982/4885NOS3 3702/4885NOS1 3790/4885 |
| US-10624875-B2 | Methods and compositions for treating schizophrenia | RAB2A, SYNGR2, GRIN2A | BRD4 436/4885NOS3 4533/4885NOS1 4653/4885 |
| US-20180125818-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | RAB2A, SYNGR2, GRIN2A | BRD4 436/4885NOS3 4533/4885NOS1 4653/4885 |
| US-20160030391-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, GRIN2D, GRM2 | BRD4 2896/4885NOS3 4562/4885NOS1 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.